Eli Lilly and Company $LLY Shares Sold by Quintet Private Bank Europe S.A.

Key Points

• Quintet Private Bank Europe S.A. reduced its Eli Lilly stake by 8.7% in Q4, selling 3,122 shares and leaving 32,628 shares worth $35.07 million (LLY is 2.0% of the fund and its 12th-largest holding).
• Eli Lilly beat estimates with Q results (EPS $7.54 vs. $7.48; revenue $19.29B vs. $17.85B, +42.6% YoY) and set FY2026 EPS guidance of 33.50–35.00.
• Positive catalysts — FDA approval of oral GLP‑1 Foundayo, a planned $6.5B Houston manufacturing plant, and the ~ $7.8B Centessa acquisition — have spurred analyst upgrades and a consensus “Moderate Buy” with an average price target of $1,222.22.

Quintet Private Bank Europe S.A. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,628 shares of the company's stock after selling 3,122 shares during the quarter. Eli Lilly and Company comprises 2.0% of Quintet Private Bank Europe S.A.'s holdings, making the stock its 12th largest holding. Quintet Private Bank Europe S.A.'s holdings in Eli Lilly and Company were worth $35,065,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Aspiriant LLC increased its stake in Eli Lilly and Company by 59.1% during the fourth quarter. Aspiriant LLC now owns 902 shares of the company's stock worth $969,000 after acquiring an additional 335 shares during the last quarter. ASL Financial LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth $1,322,000. Essex LLC increased its stake in Eli Lilly and Company by 16.0% during the fourth quarter. Essex LLC now owns 2,930 shares of the company's stock worth $3,148,000 after acquiring an additional 405 shares during the last quarter. Kavar Capital Partners Group LLC increased its stake in Eli Lilly and Company by 0.3% during the fourth quarter. Kavar Capital Partners Group LLC now owns 3,551 shares of the company's stock worth $3,816,000 after acquiring an additional 11 shares during the last quarter. Finally, Howard Capital Management Group LLC increased its stake in Eli Lilly and Company by 116.1% during the fourth quarter. Howard Capital Management Group LLC now owns 1,660 shares of the company's stock worth $1,784,000 after acquiring an additional 892 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on LLY. Argus raised their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research note on Tuesday, February 10th. Guggenheim dropped their price objective on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a "buy" rating for the company in a research note on Monday, March 30th. Royal Bank Of Canada began coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $1,250.00 price objective for the company. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $1,313.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $1,222.22.

Eli Lilly and Company Trading Down 1.0%

Shares of NYSE LLY opened at $925.93 on Tuesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The stock has a fifty day simple moving average of $990.91 and a 200-day simple moving average of $972.00. The stock has a market capitalization of $874.84 billion, a PE ratio of 40.35, a PEG ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same period in the previous year, the firm posted $5.32 earnings per share. The company's revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Foundayo, the first once-daily oral GLP‑1 for obesity; Lilly has begun rapid U.S. commercialization and analysts see a multi‑billion-dollar revenue opportunity that helps close the gap with rivals. How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval
• Positive Sentiment: Production capacity ramp: Lilly will manufacture the new oral GLP‑1 at a $6.5B Houston plant, reducing supply risk and supporting commercialization scale-up. This is a tangible capex commitment to grow supply for Foundayo. Eli Lilly's $6.5B Houston plant will make its new FDA-approved GLP-1 weight loss drug
• Positive Sentiment: Access agreement and M&A broaden growth runway: Lilly announced a U.S. pricing/access arrangement to expand Medicare/Medicaid availability for GLP‑1s and is acquiring Centessa (~$7.8B) to add sleep and neuroscience assets — both support longer‑term revenue diversification. Eli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
• Positive Sentiment: Investor sentiment lift: Several bullish notes and price-target increases have followed the Foundayo approval, reinforcing upside case for long‑term revenue and margin expansion. Eli Lilly and Company NYSE: LLY Price Target Raised to $1,294.00
• Neutral Sentiment: Sector M&A/AI tailwinds: Pharma and biotech are accelerating M&A and AI-driven R&D investments; Lilly is participating to both defend and extend its pipeline — positive strategically but benefits will play out over quarters. Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
• Neutral Sentiment: Market narrative around AI and a race to a $1T market cap keeps bullish storytelling alive, but share-price milestones remain dependent on sustained revenue/margin execution and pricing environment. Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First?
• Negative Sentiment: Price competition concerns: Coverage notes a nascent price war in the oral GLP‑1 category that could cap near‑term revenue/margin upside even after approval, pressuring the immediate stock reaction. StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod
• Negative Sentiment: Analyst repositioning: Some research shops have adjusted ratings/positions post-approval (e.g., reclassifications to Buy vs. Strong Buy), suggesting near-term profit‑taking or more cautious multiple expansion assumptions. Eli Lilly and Company NYSE: LLY Downgraded to "Buy" Rating by Wall Street Zen

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.